Anti-Asthmatics and COPD Drugs Market - Global Outlook and Forecast 2021-2027

April 2021 | 105 pages | ID: A639E572C8D6EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Anti-Asthmatics and COPD Drugs in Global, including the following market information:

Global Anti-Asthmatics and COPD Drugs Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

The global Anti-Asthmatics and COPD Drugs market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Anti-Asthmatics and COPD Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Anti-Asthmatics and COPD Drugs Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global Anti-Asthmatics and COPD Drugs Market Segment Percentages, By Type, 2020 (%)

• Anti-inflammatory Drugs
• Monoclonal Antibodies
• Combination Drugs

China Anti-Asthmatics and COPD Drugs Market, By Application, 2016-2021, 2022-2027 ($ millions)

China Anti-Asthmatics and COPD Drugs Market Segment Percentages, By Application, 2020 (%)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Anti-Asthmatics and COPD Drugs Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global Anti-Asthmatics and COPD Drugs Market Segment Percentages, By Region and Country, 2020 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Anti-Asthmatics and COPD Drugs Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total Anti-Asthmatics and COPD Drugs Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:

• Novartis AG
• Merck & Co
• GlaxoSmithKline
• Boehringer Ingelheim Gmbh
• AstraZeneca
• Roche
• Teva Pharmaceutical
• Vectura
• Pfizer
• Abbott
• Mylan
• Allergan
• Cipla
• Akorn

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Non-Cystic Fibrosis Bronchiectasis Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Non-Cystic Fibrosis Bronchiectasis Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL NON-CYSTIC FIBROSIS BRONCHIECTASIS OVERALL MARKET SIZE

2.1 Global Non-Cystic Fibrosis Bronchiectasis Market Size: 2021 VS 2027
2.2 Global Non-Cystic Fibrosis Bronchiectasis Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Non-Cystic Fibrosis Bronchiectasis Players in Global Market
3.2 Top Global Non-Cystic Fibrosis Bronchiectasis Companies Ranked by Revenue
3.3 Global Non-Cystic Fibrosis Bronchiectasis Revenue by Companies
3.4 Top 3 and Top 5 Non-Cystic Fibrosis Bronchiectasis Companies in Global Market, by Revenue in 2020
3.5 Global Companies Non-Cystic Fibrosis Bronchiectasis Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Cystic Fibrosis Bronchiectasis Players in Global Market
  3.6.1 List of Global Tier 1 Non-Cystic Fibrosis Bronchiectasis Companies
  3.6.2 List of Global Tier 2 and Tier 3 Non-Cystic Fibrosis Bronchiectasis Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global Non-Cystic Fibrosis Bronchiectasis Market Size Markets, 2021 & 2027
  4.1.2 Oral
  4.1.3 Intravenous
4.2 By Type - Global Non-Cystic Fibrosis Bronchiectasis Revenue & Forecasts
  4.2.1 By Type - Global Non-Cystic Fibrosis Bronchiectasis Revenue, 2016-2021
  4.2.2 By Type - Global Non-Cystic Fibrosis Bronchiectasis Revenue, 2022-2027
  4.2.3 By Type - Global Non-Cystic Fibrosis Bronchiectasis Revenue Market Share, 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Non-Cystic Fibrosis Bronchiectasis Market Size, 2021 & 2027
  5.1.2 Hospital
  5.1.3 Clinic
  5.1.4 Others
5.2 By Application - Global Non-Cystic Fibrosis Bronchiectasis Revenue & Forecasts
  5.2.1 By Application - Global Non-Cystic Fibrosis Bronchiectasis Revenue, 2016-2021
  5.2.2 By Application - Global Non-Cystic Fibrosis Bronchiectasis Revenue, 2022-2027
  5.2.3 By Application - Global Non-Cystic Fibrosis Bronchiectasis Revenue Market Share, 2016-2027

6 SIGHTS BY REGION

6.1 By Region - Global Non-Cystic Fibrosis Bronchiectasis Market Size, 2021 & 2027
6.2 By Region - Global Non-Cystic Fibrosis Bronchiectasis Revenue & Forecasts
  6.2.1 By Region - Global Non-Cystic Fibrosis Bronchiectasis Revenue, 2016-2021
  6.2.2 By Region - Global Non-Cystic Fibrosis Bronchiectasis Revenue, 2022-2027
  6.2.3 By Region - Global Non-Cystic Fibrosis Bronchiectasis Revenue Market Share, 2016-2027
6.3 North America
  6.3.1 By Country - North America Non-Cystic Fibrosis Bronchiectasis Revenue, 2016-2027
  6.3.2 US Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
  6.3.3 Canada Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
  6.3.4 Mexico Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
6.4 Europe
  6.4.1 By Country - Europe Non-Cystic Fibrosis Bronchiectasis Revenue, 2016-2027
  6.4.2 Germany Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
  6.4.3 France Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
  6.4.4 U.K. Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
  6.4.5 Italy Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
  6.4.6 Russia Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
  6.4.7 Nordic Countries Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
  6.4.8 Benelux Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
6.5 Asia
  6.5.1 By Region - Asia Non-Cystic Fibrosis Bronchiectasis Revenue, 2016-2027
  6.5.2 China Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
  6.5.3 Japan Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
  6.5.4 South Korea Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
  6.5.5 Southeast Asia Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
  6.5.6 India Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
6.6 South America
  6.6.1 By Country - South America Non-Cystic Fibrosis Bronchiectasis Revenue, 2016-2027
  6.6.2 Brazil Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
  6.6.3 Argentina Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Non-Cystic Fibrosis Bronchiectasis Revenue, 2016-2027
  6.7.2 Turkey Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
  6.7.3 Israel Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
  6.7.4 Saudi Arabia Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027
  6.7.5 UAE Non-Cystic Fibrosis Bronchiectasis Market Size, 2016-2027

7 PLAYERS PROFILES

7.1 Aradigm Corporation
  7.1.1 Aradigm Corporation Corporate Summary
  7.1.2 Aradigm Corporation Business Overview
  7.1.3 Aradigm Corporation Non-Cystic Fibrosis Bronchiectasis Major Product Offerings
  7.1.4 Aradigm Corporation Non-Cystic Fibrosis Bronchiectasis Revenue in Global (2016-2021)
  7.1.5 Aradigm Corporation Key News
7.2 Zambon
  7.2.1 Zambon Corporate Summary
  7.2.2 Zambon Business Overview
  7.2.3 Zambon Non-Cystic Fibrosis Bronchiectasis Major Product Offerings
  7.2.4 Zambon Non-Cystic Fibrosis Bronchiectasis Revenue in Global (2016-2021)
  7.2.5 Zambon Key News
7.3 Novartis Pharmaceuticals
  7.3.1 Novartis Pharmaceuticals Corporate Summary
  7.3.2 Novartis Pharmaceuticals Business Overview
  7.3.3 Novartis Pharmaceuticals Non-Cystic Fibrosis Bronchiectasis Major Product Offerings
  7.3.4 Novartis Pharmaceuticals Non-Cystic Fibrosis Bronchiectasis Revenue in Global (2016-2021)
  7.3.5 Novartis Pharmaceuticals Key News
7.4 Insmed Incorporated
  7.4.1 Insmed Incorporated Corporate Summary
  7.4.2 Insmed Incorporated Business Overview
  7.4.3 Insmed Incorporated Non-Cystic Fibrosis Bronchiectasis Major Product Offerings
  7.4.4 Insmed Incorporated Non-Cystic Fibrosis Bronchiectasis Revenue in Global (2016-2021)
  7.4.5 Insmed Incorporated Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Anti-Asthmatics and COPD Drugs Market Opportunities & Trends in Global Market
Table 2. Anti-Asthmatics and COPD Drugs Market Drivers in Global Market
Table 3. Anti-Asthmatics and COPD Drugs Market Restraints in Global Market
Table 4. Key Players of Anti-Asthmatics and COPD Drugs in Global Market
Table 5. Top Anti-Asthmatics and COPD Drugs Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Anti-Asthmatics and COPD Drugs Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Anti-Asthmatics and COPD Drugs Revenue Share by Companies, 2016-2021
Table 8. Global Companies Anti-Asthmatics and COPD Drugs Product Type
Table 9. List of Global Tier 1 Anti-Asthmatics and COPD Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Anti-Asthmatics and COPD Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Anti-Asthmatics and COPD Drugs Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Anti-Asthmatics and COPD Drugs Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Anti-Asthmatics and COPD Drugs Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Anti-Asthmatics and COPD Drugs Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Anti-Asthmatics and COPD Drugs Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Anti-Asthmatics and COPD Drugs Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2022-2027
Table 30. Novartis AG Corporate Summary
Table 31. Novartis AG Anti-Asthmatics and COPD Drugs Product Offerings
Table 32. Novartis AG Anti-Asthmatics and COPD Drugs Revenue (US$, Mn), (2016-2021)
Table 33. Merck & Co Corporate Summary
Table 34. Merck & Co Anti-Asthmatics and COPD Drugs Product Offerings
Table 35. Merck & Co Anti-Asthmatics and COPD Drugs Revenue (US$, Mn), (2016-2021)
Table 36. GlaxoSmithKline Corporate Summary
Table 37. GlaxoSmithKline Anti-Asthmatics and COPD Drugs Product Offerings
Table 38. GlaxoSmithKline Anti-Asthmatics and COPD Drugs Revenue (US$, Mn), (2016-2021)
Table 39. Boehringer Ingelheim Gmbh Corporate Summary
Table 40. Boehringer Ingelheim Gmbh Anti-Asthmatics and COPD Drugs Product Offerings
Table 41. Boehringer Ingelheim Gmbh Anti-Asthmatics and COPD Drugs Revenue (US$, Mn), (2016-2021)
Table 42. AstraZeneca Corporate Summary
Table 43. AstraZeneca Anti-Asthmatics and COPD Drugs Product Offerings
Table 44. AstraZeneca Anti-Asthmatics and COPD Drugs Revenue (US$, Mn), (2016-2021)
Table 45. Roche Corporate Summary
Table 46. Roche Anti-Asthmatics and COPD Drugs Product Offerings
Table 47. Roche Anti-Asthmatics and COPD Drugs Revenue (US$, Mn), (2016-2021)
Table 48. Teva Pharmaceutical Corporate Summary
Table 49. Teva Pharmaceutical Anti-Asthmatics and COPD Drugs Product Offerings
Table 50. Teva Pharmaceutical Anti-Asthmatics and COPD Drugs Revenue (US$, Mn), (2016-2021)
Table 51. Vectura Corporate Summary
Table 52. Vectura Anti-Asthmatics and COPD Drugs Product Offerings
Table 53. Vectura Anti-Asthmatics and COPD Drugs Revenue (US$, Mn), (2016-2021)
Table 54. Pfizer Corporate Summary
Table 55. Pfizer Anti-Asthmatics and COPD Drugs Product Offerings
Table 56. Pfizer Anti-Asthmatics and COPD Drugs Revenue (US$, Mn), (2016-2021)
Table 57. Abbott Corporate Summary
Table 58. Abbott Anti-Asthmatics and COPD Drugs Product Offerings
Table 59. Abbott Anti-Asthmatics and COPD Drugs Revenue (US$, Mn), (2016-2021)
Table 60. Mylan Corporate Summary
Table 61. Mylan Anti-Asthmatics and COPD Drugs Product Offerings
Table 62. Mylan Anti-Asthmatics and COPD Drugs Revenue (US$, Mn), (2016-2021)
Table 63. Allergan Corporate Summary
Table 64. Allergan Anti-Asthmatics and COPD Drugs Product Offerings
Table 65. Allergan Anti-Asthmatics and COPD Drugs Revenue (US$, Mn), (2016-2021)
Table 66. Cipla Corporate Summary
Table 67. Cipla Anti-Asthmatics and COPD Drugs Product Offerings
Table 68. Cipla Anti-Asthmatics and COPD Drugs Revenue (US$, Mn), (2016-2021)
Table 69. Akorn Corporate Summary
Table 70. Akorn Anti-Asthmatics and COPD Drugs Product Offerings
Table 71. Akorn Anti-Asthmatics and COPD Drugs Revenue (US$, Mn), (2016-2021)

List Of Figures

LIST OF FIGURES

Figure 1. Anti-Asthmatics and COPD Drugs Segment by Type
Figure 2. Anti-Asthmatics and COPD Drugs Segment by Application
Figure 3. Global Anti-Asthmatics and COPD Drugs Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Anti-Asthmatics and COPD Drugs Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Anti-Asthmatics and COPD Drugs Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Anti-Asthmatics and COPD Drugs Revenue in 2020
Figure 8. By Type - Global Anti-Asthmatics and COPD Drugs Revenue Market Share, 2016-2027
Figure 9. By Application - Global Anti-Asthmatics and COPD Drugs Revenue Market Share, 2016-2027
Figure 10. By Region - Global Anti-Asthmatics and COPD Drugs Revenue Market Share, 2016-2027
Figure 11. By Country - North America Anti-Asthmatics and COPD Drugs Revenue Market Share, 2016-2027
Figure 12. US Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Anti-Asthmatics and COPD Drugs Revenue Market Share, 2016-2027
Figure 16. Germany Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 17. France Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Anti-Asthmatics and COPD Drugs Revenue Market Share, 2016-2027
Figure 24. China Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 28. India Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Anti-Asthmatics and COPD Drugs Revenue Market Share, 2016-2027
Figure 30. Brazil Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Anti-Asthmatics and COPD Drugs Revenue Market Share, 2016-2027
Figure 33. Turkey Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Anti-Asthmatics and COPD Drugs Revenue, (US$, Mn), 2016-2027
Figure 37. Novartis AG Anti-Asthmatics and COPD Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Merck & Co Anti-Asthmatics and COPD Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. GlaxoSmithKline Anti-Asthmatics and COPD Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. Boehringer Ingelheim Gmbh Anti-Asthmatics and COPD Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. AstraZeneca Anti-Asthmatics and COPD Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Roche Anti-Asthmatics and COPD Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. Teva Pharmaceutical Anti-Asthmatics and COPD Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 44. Vectura Anti-Asthmatics and COPD Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 45. Pfizer Anti-Asthmatics and COPD Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 46. Abbott Anti-Asthmatics and COPD Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 47. Mylan Anti-Asthmatics and COPD Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 48. Allergan Anti-Asthmatics and COPD Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 49. Cipla Anti-Asthmatics and COPD Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)